What is Aura Biosciences Inc (AURA) stock price today?

Aura Biosciences Inc (AURA) currently trades at $7.05 per share. The stock has a market capitalization of $432.06M and a P/E ratio of —x.

Is AURA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Aura Biosciences Inc has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is -0.97.

Is Aura Biosciences Inc financially healthy?

Aura Biosciences Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of -0.97 places it in the distress.

AURA

Aura Biosciences Inc

NASDAQ: AURA · HEALTHCARE · BIOTECHNOLOGY

$7.05

+4.75% today

Updated 2026-04-30

Market cap

$432.06M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.76

Dividend yield

—

52W range

$4 – $8

Volume

0.3M

Market cap

$432.06M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.76

Dividend yield

—

52W range

$4 – $8

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-1.0

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$20.40

+189.36%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.11x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -0.97 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-20.64M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-58.76M	$-76.41M	$-86.92M	$-106.19M	$-25.56M
EPS	—	—	—	—	$-1.76
Free cash flow	$-55.70M	$-64.56M	$-81.06M	$-85.19M	$-20.64M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-02	PLAVSIC, MARK	Buy	112,661	—
2026-03-02	PLAVSIC, MARK	Buy	62,339	—
2026-03-02	KILROY, CONOR	Buy	112,661	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
AURA	$432.06M	26	4.3	3.0	5.0	6.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Aura Biosciences Inc trades at $7.05. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -0.97, it sits in the distress.

Frequently asked questions

What is Aura Biosciences Inc's stock price?

Aura Biosciences Inc (AURA) trades at $7.05.

Is Aura Biosciences Inc overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell).

What is the price target of Aura Biosciences Inc (AURA)?

The analyst target price is $20.40, representing +189.4% upside from the current price of $7.05.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

-0.97 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.aurabiosciences.com

Quick metrics

P/S ratio—

ROE-73.50%

Beta0.35

50D MA$6.42

200D MA$6.15

Shares out0.06B

Float0.04B

Short ratio—

Avg volume0.3M

Performance

1 week-7.08%

1 month+12.26%

3 months+28.41%

YTD+27.71%

1 year—

3 years—

5 years—

Compare

AURA vs LLY →AURA vs JNJ →AURA vs ABBV →Stock screener →